04693124001
Roche
cOmplete™, Mini Protease Inhibitor Cocktail
Tablets provided in EASYpacks
Sinônimo(s):
protease inhibitor
Faça loginpara ver os preços organizacionais e de contrato
About This Item
Código UNSPSC:
12352204
NACRES:
NA.21
Produtos recomendados
forma
tablet
embalagem
pack of 30 tablets (individually packed in foil blister packs)
fabricante/nome comercial
Roche
solubilidade
aqueous buffer: soluble
water: soluble
temperatura de armazenamento
2-8°C
Descrição geral
cOmplete, Mini Protease Inhibitor Tablets, inhibit a broad spectrum of serine, cysteine and metalloproteases, as well as calpains. Due to the optimized composition of the tablets, they show excellent inhibition effects, and are well suited for the protection of proteins isolated from animal tissues, plants, yeast, and bacteria.
cOmplete, Mini, contains EDTA and both irreversible and reversible protease inhibitors.
cOmplete, Mini, contains EDTA and both irreversible and reversible protease inhibitors.
Especificidade
For the inhibition of serine, cysteine, and metalloproteases in bacterial, mammalian, yeast, and plant cell extracts.
Aplicação
cOmplete™, Mini Protease Inhibitor Cocktail has been used as a component in
- mammalian-protein extraction reagent (M-PER) for lysis of glioma stem cells (GSCs)
- sodium dodecyl sulphate-tris buffered saline (SDS-TBS) for the homogenisation of brain tissues
- radioimmunoprecipitation assay (RIPA) buffer for lysis of human embryonic stem cells (hESCs)
cOmplete™, Mini, is used for the inhibition of serine, cysteine, and metalloproteases in bacterial, mammalian, yeast, and plant cell extracts.
cOmplete, Mini, contains both reversible and irreversible protease inhibitors. Therefore, we recommend the addition of cOmplete, Mini, to all stock buffers and solutions normally protected with protease inhibitors, and not just during the initial purification steps.
cOmplete, Mini, contains EDTA (1 tablet yields a 1 mM EDTA solution in 10 ml). Therefore, the extraction buffer should not contain divalent cations like Ca2+, Mg2+, or Mn2+, otherwise the inhibition of the metalloproteases might be incomplete. If the protein of interest will be purified by IMAC (Immobilized Metal Affinity Chromatography), for example, Poly-His-tagged recombinant proteins, EDTA has to be eliminated (e.g., by dialysis) prior to the chromatography.
Alternatively, the product cOmplete, Mini, EDTA-free, can be used. These tablets are identical to cOmplete, Mini, with the exception that no EDTA or other chelating agent is present.
cOmplete, Mini Tablets, inhibit proteolytic activity in small extraction volumes (up to 10 ml). If you are working with a larger volume (up to 50 ml), we recommend to use a different cOmplete product. The composition of the cOmplete Tablet is identical to the cOmplete, Mini Tablet, therefore, comparable results are achieved with both product types.
cOmplete, Mini, contains both reversible and irreversible protease inhibitors. Therefore, we recommend the addition of cOmplete, Mini, to all stock buffers and solutions normally protected with protease inhibitors, and not just during the initial purification steps.
cOmplete, Mini, contains EDTA (1 tablet yields a 1 mM EDTA solution in 10 ml). Therefore, the extraction buffer should not contain divalent cations like Ca2+, Mg2+, or Mn2+, otherwise the inhibition of the metalloproteases might be incomplete. If the protein of interest will be purified by IMAC (Immobilized Metal Affinity Chromatography), for example, Poly-His-tagged recombinant proteins, EDTA has to be eliminated (e.g., by dialysis) prior to the chromatography.
Alternatively, the product cOmplete, Mini, EDTA-free, can be used. These tablets are identical to cOmplete, Mini, with the exception that no EDTA or other chelating agent is present.
cOmplete, Mini Tablets, inhibit proteolytic activity in small extraction volumes (up to 10 ml). If you are working with a larger volume (up to 50 ml), we recommend to use a different cOmplete product. The composition of the cOmplete Tablet is identical to the cOmplete, Mini Tablet, therefore, comparable results are achieved with both product types.
Características e benefícios
- Convenience: Simply push the quick-dissolving tablet through the foil packaging of the EASYpack into your buffer.
- Complete protection: Instantly protect your proteins against a broad range of proteases (see Table 1).
- Flexible: Protect proteins in extracts from almost any tissue or cell, including animals, plants, yeast, bacteria, or fungi.
- Safe: Choose non-toxic inhibitors that pose no risk to you or those around you.
- Suitable for IMAC purification: Purify poly-histidine tagged proteins with cOmplete His-Tag Purification Resin.
Embalagem
30 individually packed cOmplete Protease Inhibitor Cocktail Tablets in foil blisters. Each tablet is sufficient for a volume of 10 ml solution.
Componentes
Proprietary mixture of several protease inhibitors with broad inhibitory specificity.
Qualidade
Performance-tested with pancreas extract.
forma física
Tablets in foil blister packs
Nota de preparo
Working concentration: 1 tablet per 10 ml extraction solution
Preparation of Working Solution:
Carefully push the tablet through the foil packaging using the base of your thumb (not fingernail) to prevent breakage of tablets.
One cOmplete Mini tablet is sufficient for the inhibition of the proteolytic activity in 10 ml extraction solution. When very high proteolytic activity is present, one tablet should be used for 7 ml extraction buffer. The tablets can be added directly to the extraction medium. Alternatively, a stock solution (7 X conc.) can be prepared.
Stock solution (7 X conc.):
Dissolve one cOmplete Mini tablet in 1.5 ml dist. water or in 1.5 ml 100 mM phosphate buffer, pH 7.0.
Storage conditions (working solution): The stock solution can be stored at 2 to 8 °C for 1 to 2 weeks, or at least 12 weeks at -15 to -25 °C.
Preparation of Working Solution:
Carefully push the tablet through the foil packaging using the base of your thumb (not fingernail) to prevent breakage of tablets.
One cOmplete Mini tablet is sufficient for the inhibition of the proteolytic activity in 10 ml extraction solution. When very high proteolytic activity is present, one tablet should be used for 7 ml extraction buffer. The tablets can be added directly to the extraction medium. Alternatively, a stock solution (7 X conc.) can be prepared.
Stock solution (7 X conc.):
Dissolve one cOmplete Mini tablet in 1.5 ml dist. water or in 1.5 ml 100 mM phosphate buffer, pH 7.0.
Storage conditions (working solution): The stock solution can be stored at 2 to 8 °C for 1 to 2 weeks, or at least 12 weeks at -15 to -25 °C.
Reconstituição
Soluble in aqueous buffers, or add directly to extraction media. Alternatively, prepare 7x stock solutions in 1.5 ml water or 100 mM phosphate buffer, pH 7.0. Stock solution is stable for 1-2 weeks at 2 to 8 °C or at least 12 weeks at -15 to -25 °C; can be used in thiol-containing solutions at 15 to 25 °C.
Outras notas
For life science research only. Not for use in diagnostic procedures.
Informações legais
cOmplete is a trademark of Roche
produto relacionado
Nº do produto
Descrição
Preços
Palavra indicadora
Warning-Warning
Frases de perigo
Classificações de perigo
Eye Irrit. 2 - Skin Irrit. 2
Código de classe de armazenamento
11 - Combustible Solids
Classe de risco de água (WGK)
WGK 2
Ponto de fulgor (°F)
does not flash
Ponto de fulgor (°C)
does not flash
Certificados de análise (COA)
Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.
Já possui este produto?
Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.
Os clientes também visualizaram
The antibiotic clofoctol suppresses glioma stem cell proliferation by activating KLF13
Hu Y, et al.
The Journal of Clinical Investigation, 129(8) (2019)
Wenping Ma et al.
Neuroscience bulletin, 36(4), 359-371 (2019-10-28)
Gliomas are the most commonly occurring tumors of the central nervous system. Glioblastoma multiforme (GBM) is the most malignant and aggressive brain cancer in adults. Further understanding of the mechanisms underlying the aggressive nature of GBM is urgently needed. Here
Yu Sun et al.
Molecular medicine reports, 24(5) (2021-09-10)
Glioblastoma (GBM) is one of the most common and malignant types of primary cancer in the central nervous system; however, the clinical outcomes of patients with GBM remain poor. Circular RNAs (circRNAs) have been revealed to serve important roles in
Characterization of the 18 kda translocator protein (tspo) expression in post-mortem normal and alzheimer's disease brains
Gui Y, et al.
Brain Pathology, 1-14 (2019)
Jakob Triebel et al.
European journal of endocrinology, 161(2), 345-353 (2009-05-30)
In vitro experiments and in vivo studies on rodents demonstrate that N-terminal 14, 15, 16, 17, and 18 kDa fragments prolactin-related vasoinhibin (PRL-V) of human PRL are natural inhibitors of neovascularization in the retina and elsewhere. These N-terminal PRL fragments
Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.
Entre em contato com a assistência técnica